Catalyst Wire Dossier Catalyst Wire Dossier

Keytruda (Pembrolizumab)

pembrolizumab · Merck & Co.
Drug timelines are a Plus or Pro feature.

29 regulatory and trial events tracked for Keytruda (Pembrolizumab), covering 2017-11-24 to 2026-04-15. Get the full timeline:

Most recent: Clinical Trial Update: PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma [Phase 2]

See pricing